Just in case anyone is interested:
http://www.vionpharm.com
Cloretazine®
Protocol ID Protocol Title Site Name
CLI-033 A Phase II Study of Cloretazine® for Patients with Acute Myelogeneous Leukemia or High-Risk Myelodysplasia MD Anderson Cancer Center/University of Texas Houston, TX
–
Duke University Comprehensive Cancer Center, Durham, North Carolina
–
The Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore ,MD
–
Institut Paoli-Calmettes, Marseille, France
–
King’s College School of Medicine, London, UK
CLI-036 A Phase I Study of Cloretazine® and Temozolomide in Patients with Hematologic Malignancies The Ireland Cancer Center at Case Western Reserve University
Cleveland, Ohio
CLI-037 A Phase III Randomized Study
of Cloretazine® and Cytosine Arabinoside (AraC) in Patients with Acute Myelogenous Leukemia in First Relapse 50 sites opened in North America and Europe
CLI-039 A Phase II Trial of Cloretazine® for Patients with Relapsed or Refractory Small Cell Lung Cancer Yale University
New Haven, CT
–
Nevada Cancer Institute
Las Vegas, NV
–
Sarah Cannon Cancer Center
Nashville, TN
–
MD Anderson Cancer Center/University of Texas Houston, TX
CLI-041 A Phase I/II Study of Cloretazine® in Patients with Refractory Relapsed Chronic Lymphocytic Leukemia or Richter’s Syndrome MD Anderson Cancer Center/University of Texas Houston, TX
.
